Capricor Therapeutics Inc. (4LN2)
XDUS 
Summary
4LN2 Chart
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics NASDAQ: CAPR executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis
Capricor is rated a speculative Buy ahead of its August 22 PDUFA for deramiocel in Duchenne muscular dystrophy. Recent HOPE-3 data disclosures address most prior concerns about primary and cardiac endpoints, reducing trial-related risks. Key remaining risks include commercial disputes with NS Pharma/Nippon Shinyaku and limited initial manufacturing capacity.
Capricor Therapeutics Inc. (4LN2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Capricor Therapeutics Inc. ever had a stock split?
Capricor Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Linda Marbán CEO | XDUS Exchange | US14070B3096 ISIN |
| US Country | 160 Employees | 5 Jun 2019 Last Dividend | 5 Jun 2019 Last Split | 13 Feb 2007 IPO Date |
Overview
Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm established in 2005, with its headquarters located in San Diego, California. The company is dedicated to the development of revolutionary cell and exosome-based therapeutics aimed at treating a variety of diseases that currently have unmet medical needs, with a particular focus on Duchenne Muscular Dystrophy (DMD). Through its advanced research and clinical trials, Capricor Therapeutics strives to bring innovative treatments to patients suffering from DMD and other serious conditions. The company has established several important collaborations and licensing agreements with prestigious institutions and companies, including Nippon Shinyaku Co. Ltd., National Institute of Allergy and Infectious Diseases, Johns Hopkins University, Cedars-Sinai Medical Center, and Life Technologies Corporation, to further its research and development efforts.
Products and Services
- CAP-1002
- StealthX
- CAP-2003
This allogeneic cardiac-derived cell therapy is Capricor Therapeutics’ leading candidate, specifically aimed at treating patients with late-stage Duchenne muscular dystrophy (DMD). Having completed phase 3 clinical trials, CAP-1002 represents a significant advancement in the quest for effective DMD therapies, showing promise in addressing the needs of patients suffering from this debilitating disease.
StealthX is an innovative engineered exosome-based vaccine candidate that is currently under phase 1 clinical study. This candidate is designed for a multitude of therapeutic applications, including the delivery of targeted RNA, proteins, and small molecule therapeutics. StealthX is aimed at treating or preventing a variety of diseases, showcasing Capricor’s dedication to leveraging cutting-edge science in its therapeutic development.
Currently in the pre-clinical development stage, CAP-2003 is being explored for its potential in treating trauma-related injuries and conditions. This further exemplifies Capricor Therapeutics’ commitment to expanding its portfolio of treatments and addressing a broader range of medical concerns that lack effective treatments.
